Archived Facts

Posts Tagged ‘Genzyme’

LYON (Reuters) – Sanofi’s Genzyme unit has received positive feedback from U.S. doctors after the recent launch of multiple sclerosis pill Aubagio and moving toward refiling its FDA application for MS drug Lemtrada, senior executives said on Friday.

Related Posts:

Shares of Genzyme Corp. rose Friday evening on a Wall Street Journal report that the biotech drugmaker is discussing a more lucrative deal with French giant Sanofi-Aventis, which has been unsuccessfully pursuing the company since last July.
All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Shares of Genzyme Corp. rose Friday evening on a Wall Street Journal report that the biotech drugmaker is discussing a more lucrative deal with French giant Sanofi-Aventis, which has been unsuccessfully pursuing the company since last July.
All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Shares of Genzyme Corp. rose Friday evening on a Wall Street Journal report that the biotech drugmaker is discussing a more lucrative deal with French giant Sanofi-Aventis, which has been unsuccessfully pursuing the company since last July.
All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Genzyme Corp. on Friday forecast 2011 profit well above Wall Street expectations, and said the outlook makes the biotechnology company worth $89 per share — not the $69 per share offered by Sanofi-Aventis SA.

See the original post:
Genzyme:New 2011 outlook makes co. worth $89-share

Related Posts:

Genzyme Corp made its case for why it is worth more than the $18.5 billion being offered by France’s Sanofi-Aventis, forecasting peak sales for its experimental multiple sclerosis drug Campath and 2011 profit well above Wall Street estimates.

View full post on All News, Video and Posts related to SECTOR: Health Care

Related Posts:

Biotech firm Genzyme Corp. on Thursday said its board of directors has rejected Sanofi-Aventis SA’s $69 per share offer and has recommended that Genzyme shareholders do not sell their shares to the French drugmaker.

Here is the original post:
Genzyme board rejects Sanofi $69-a-share offer

Related Posts:

After Genzyme rejected a takeover bid from Sanofi-Aventis, Brian Stutland explained how options can be used to play Sanofi.

More here:
Options Action: Sanofi-Aventis on Genzyme Takeover Bid

Related Posts:

Here’s how French pharmaceutical giant Sanofi-Aventis SA, which has initiated a hostile takeover attempt for Genzyme Corp. of Cambridge, Mass., describes how the proposed $18.5 billion deal would benefit the two companies and their shareholders:

See the original post here:
How Sanofi sees benefits of Genzyme takeover

Related Posts:

Sanofi-Aventis says it is launching a hostile $69 per share takeover battle for US biotech company Genzyme Corp.

Read more here:
Sanofi-Aventis lauches Genzyme takeover battle

Related Posts: